-- EyePoint Pharmaceuticals shares fell more than 26% in premarket activity Monday after the company said a trial of its potential diabetes treatment Duravyu failed to meet the primary endpoint of...
Related Keywords
, Eyepoint Pharmaceuticals Inc , Eyepoint Pharmaceuticals , Markets ,
comparemela.com © 2020. All Rights Reserved.